Clinical Trial Update: A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of TBI-1401(HF10) and ipilimumab in Japanese patients with unresectable or metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TBI-1401(HF10) (HF10 oncolytic herpes simplex virus type 1)
• Yervoy (Ipilimumab) (Ipilimumab)

Snippet

Sponsor: Takara Bio Inc. | Conditions: Melanoma Stage III, Melanoma Stage IV | Phase 2 | Status: COMPLETED